Free Trial
NASDAQ:ADGM

Adagio Medical 5/15/2025 Earnings Report

Adagio Medical logo
$2.03 +0.32 (+18.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.99 -0.04 (-2.17%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adagio Medical EPS Results

Actual EPS
-$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Adagio Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adagio Medical Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Adagio Medical's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Adagio Medical Earnings Headlines

Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.tc pixel
Adagio Medical Posts Narrower Q2 Loss
See More Adagio Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adagio Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagio Medical and other key companies, straight to your email.

About Adagio Medical

Adagio Medical (NASDAQ:ADGM), Inc. (NASDAQ: ADGM) is a medical device company focused on the development and commercialization of a noninvasive system for monitoring intracranial pressure (ICP). The company’s proprietary technology uses tympanic membrane displacement to provide clinicians with real-time estimates of ICP without the risks associated with invasive catheter methods. This approach is designed to improve patient safety, reduce complications, and streamline neurological monitoring in acute and critical care settings.

At the core of Adagio Medical’s pipeline is its ADGM System, which is intended for use in hospitals, emergency departments, and other clinical environments where rapid and accurate assessment of ICP is crucial. The system leverages advanced signal processing and hardware integration to capture subtle changes in ear canal pressure, translating these measurements into clinically actionable ICP values. Adagio Medical is pursuing regulatory review in key markets and has engaged in pilot studies with leading medical institutions to validate performance and ease of use.

Headquartered in Milpitas, California, Adagio Medical serves a global audience of neurosurgeons, neurologists, and critical care specialists. The company has established collaborations with academic medical centers and research organizations to further refine its technology and expand potential applications, including traumatic brain injury, hydrocephalus management, stroke care, and pediatric neurology. These partnerships help support ongoing clinical trials and product development initiatives aimed at broadening the system’s utility across various patient populations.

Led by CEO Keld Refsgaard, PhD, Adagio Medical draws upon a team of engineers, clinicians, and regulatory experts to drive innovation and navigate complex approval pathways. The company’s management emphasizes a commitment to scientific rigor, patient-centric design, and strategic collaboration as it works toward commercial launch and market adoption of its noninvasive ICP monitoring solution.

View Adagio Medical Profile

More Earnings Resources from MarketBeat